The main department of described VC is located in the New York. The fund was located in North America if to be more exact in United States.
The overall number of key employees were 8.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Innovatus Capital Partners, startups are often financed by CRG L.P., Windham Venture Partners, Tullis Health Investors. The meaningful sponsors for the fund in investment in the same round are WuXi NextCODE, Telegraph Hill Partners, TPG Biotech.
The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Innovatus Capital Partners works on 21 percentage points more the average amount of lead investments. Speaking about the real fund results, this VC is 55 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2019. The fund is generally included in less than 2 deals every year.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline DNAnexus, Personal Genome Diagnostics (PGD) The fund has no exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Biotechnology, Bioinformatics. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund.
|Allstate Strategic Ventures||Illinois, Northbrook, United States|
|CIMB||Kuala Lumpur, Malaysia|
|Columbia Ventures Corporation||-|
|Funderbeam||England, London, United Kingdom|
|Gentera||Distrito Federal, Mexico, Mexico City|
|Hengying Capital||Beijing, Beijing, China|
|Impact Venture||England, London, United Kingdom|
|K5 Global||California, Los Angeles, United States|
|LUMO labs||Eindhoven, Noord-Brabant, The Netherlands|
|Musashi Securities||Japan, Saitama, Saitama Prefecture|
|PJC Capital||Minneapolis, Minnesota, United States|
|prominent venture capital||-|
|Qingkong Jinxin Blue Microbiology Fund||-|
|Surround Ventures||New York, New York, United States|
|The Rahn Group||Minneapolis, Minnesota, United States|
|U.S. Army Combat Capabilities Development Command Army Research Laboratory||Louisiana, Maryland, United States|
|$5M||07 Jun 2022||California, United States|
|$200M||08 Mar 2022||Mountain View, California, United States|
|$35M||21 Dec 2021||Austin, Texas, United States|
|$105M||16 Nov 2021||City of Saint Louis, Missouri, United States|
|$27M||25 Oct 2021||Vista, California, United States|
|$2M||13 Sep 2021||-|
|$260M||15 Jul 2021||California, United States|
Personal Genome Diagnostics
|$103M||10 Feb 2021||Baltimore, Maryland, United States|
|$50M||05 Dec 2019||Marlborough, Massachusetts, United States|
– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.